From Neurology (L.G., O.O.-W., A.T.-B., D.W., P.V., G.Q.), CHU de Rouen; Radiology (G.B., F.B.), CHRU de Tours; Service des Urgences Neurovasculaires (J.C., S.A.), Hôpital Pitié-Salpêtrière, Sorbonne Université, AP-HP, Stare Team, iCRIN, Institut du Cerveau, Paris; Neurology (D. Renard, A.W., E. Thouvenot), CHU de Nîmes; Neurology (N.R., C.G., J.P.), CHU de Toulouse; Neurology (X.A., C.A., P.M.L.), CHU de Montpellier; Radiology (E.G.), CHU de Rouen; Neurology (P.K.), CHU de Luxembourg; Neurology (D.S., N.O., T.A.), CH de Perpignan; Neurology (M.F.), Hospices Civils de Lyon; Neurology (F.P.), CH de Versailles; Neurology (G.T., C.I.), GHU Paris; Geriatric Medicine (M. Verny), Hôpital Pitié-Salpêtrière, AP-HP, Paris; Neurology (L.H.), CHRU de Nancy; Neurology (M. Gaudron), CHRU de Tours; Neurology (S.V.), CHU de Rennes; Neurology (N.D., H.Z.), CHU de Lille; Neurology (B.G.), CHU de Nantes; Université Grenoble Alpes (O.D.), INSERM, U1216, Neurology, CHU de Grenoble Alpes, Grenoble Institute Neurosciences; Neurology (S.G.), CHU de Angers; UR2CA-URRIS (B.C.), Stroke Unit, CHU Pasteur 2, Nice Cote d'Azur University; Internal Medicine (M.L., S.B.), CHU de Nice; Internal Medicine (M.G.-V.), Hôpital Croix-Rousse, Lyon; Neurology (L.K.), CHRU de Strasbourg; Neurology (L.D.), CH de Lorient, France; Neurology (N.L.), CHU de Liège/CHR la Citadelle, Liège, Belgique; Neurology (S.L.), Hôpital du Sacré-cœur de Montréal; Neurology (A.P.), CH de l'Université de Montréal, Québec, Canada; Internal Medicine (A.R., B.T.), Université Paris-Cité, Hôpital Cochin, AP-HP; Neurology (D.W.-L.), Hôpital Foch, Suresnes; Internal Medicine (M. Vautier), Hôpital Pitié-Salpêtrière, Paris; Neurology (S.C.), CH de Gonesse; Internal Medicine (A. Neel), CHU de Nantes; Université Caen-Normandie (O.M., R.S., E. Touzé, A. Nehme), Neurology, CHU de Caen-Normandie; Internal Medicine (T.P.), Hôpital Bichat; Internal Medicine (C.C.-O.), Hôpital Lariboisière; Neurology (E.J.), Hôpital Lariboisière, Paris; Neurology (M.S.), HIA Sainte-Anne, Toulon; Neurology (L.P.-M.), CHU de Clermont-Ferrand; Neurology (M.A.K.), CH Troyes; Neurology (F.L.), CH d'Orsay; Neurology, CH de Saint-Denis; Université de Franche-Comté (E.M.), LINC Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive et CMRR, Service de Neurologie, CHU de Besançon; Neurology (Q.T., M. Graber), CHU de Dijon; Neurology (Y.B.), CH de Béziers; Neurology (G.B.-F., D. Ratiu), CH de Narbonne, France; Vasculitis Clinic (C.P.), Mount Sinai Hospital, University of Toronto, Ontario, Canada; and Université Caen-Normandie (H.D.B.), Internal Medicine, CHU de Caen-Normandie, France.
Neurology. 2024 Jul 23;103(2):e209548. doi: 10.1212/WNL.0000000000209548. Epub 2024 Jun 20.
Cerebral amyloid angiopathy-related inflammation (CAA-RI) and biopsy-positive primary angiitis of the CNS (BP-PACNS) have overlapping clinicoradiologic presentations. It is unknown whether clinical and radiologic features can differentiate CAA-RI from BP-PACNS and whether both diseases have different relapse rates. The objectives of this study were to compare clinicoradiologic presentations and relapse rates in patients with CAA-RI vs BP-PACNS.
Patients with CAA-RI and BP-PACNS were enrolled from 2 retrospective multicenter cohorts. Patients with CAA-RI were biopsy-positive or met probable clinicoradiologic criteria. Patients with BP-PACNS had histopathologic confirmation of CNS angiitis, with no secondary etiology. A neuroradiologist read brain MRIs, blinded to the diagnosis of CAA-RI or BP-PACNS. Clinicoradiologic features were compared using univariable logistic regression models. Relapse rates were compared using a univariable Fine-Gray subdistribution hazard model, with death as a competing risk.
This study enrolled 104 patients with CAA-RI (mean age 73 years, 48% female sex) and 52 patients with BP-PACNS (mean age 45 years, 48% female sex). Patients with CAA-RI more often had white matter hyperintense lesions meeting the probable CAA-RI criteria (93% vs 51%, < 0.001), acute subarachnoid hemorrhage (15% vs 2%, = 0.02), cortical superficial siderosis (27% vs 4%, < 0.001), ≥1 lobar microbleed (94% vs 26%, < 0.001), past intracerebral hemorrhage (17% vs 4%, = 0.04), ≥21 visible centrum semiovale perivascular spaces (34% vs 4%, < 0.01), and leptomeningeal enhancement (70% vs 27%, < 0.001). Patients with BP-PACNS more often had headaches (56% vs 31%, < 0.01), motor deficits (56% vs 36%, = 0.02), and nonischemic parenchymal gadolinium enhancement (82% vs 16%, < 0.001). The prevalence of acute ischemic lesions was 18% in CAA-RI and 22% in BP-PACNS ( = 0.57). The features with the highest specificity for CAA-RI were acute subarachnoid hemorrhage (98%), cortical superficial siderosis (96%), past intracerebral hemorrhage (96%), and ≥21 visible centrum semiovale perivascular spaces (96%). The probable CAA-RI criteria had a 71% sensitivity (95% CI 44%-90%) and 91% specificity (95% CI 79%-98%) in differentiating biopsy-positive CAA-RI from BP-PACNS. The rate of relapse in the first 2 years after remission was lower in CAA-RI than in BP-PACNS (hazard ratio 0.46, 95% CI 0.22-0.96, = 0.04).
Clinicoradiologic features differed between patients with CAA-RI and those with BP-PACNS. Specific markers for CAA-RI were hemorrhagic signs of subarachnoid involvement, past intracerebral hemorrhage, ≥21 visible centrum semiovale perivascular spaces, and the probable CAA-RI criteria. A biopsy remains necessary for diagnosis in some cases of CAA-RI. The rate of relapse in the first 2 years after disease remission was lower in CAA-RI than in BP-PACNS.
脑淀粉样血管病相关性炎症（CAA-RI）和经活检证实的原发性中枢神经系统血管炎（BP-PACNS）具有重叠的临床影像学表现。目前尚不清楚临床和影像学特征是否可以区分 CAA-RI 和 BP-PACNS，以及这两种疾病是否具有不同的复发率。本研究的目的是比较 CAA-RI 与 BP-PACNS 患者的临床影像学表现和复发率。
本研究纳入了来自 2 个回顾性多中心队列的 CAA-RI 和 BP-PACNS 患者。CAA-RI 患者经活检证实或符合可能的临床影像学标准。BP-PACNS 患者具有中枢神经系统血管炎的组织病理学证实，无继发性病因。神经放射科医生对脑 MRI 进行阅读，对 CAA-RI 或 BP-PACNS 的诊断不了解。使用单变量逻辑回归模型比较临床影像学特征。使用单变量 Fine-Gray 亚分布风险模型比较复发率，以死亡为竞争风险。
本研究纳入了 104 例 CAA-RI 患者（平均年龄 73 岁，48%为女性）和 52 例 BP-PACNS 患者（平均年龄 45 岁，48%为女性）。与 BP-PACNS 患者相比，CAA-RI 患者更常出现符合可能的 CAA-RI 标准的脑白质高信号病变（93% vs 51%， < 0.001）、急性蛛网膜下腔出血（15% vs 2%， = 0.02）、皮质表浅铁沉积（27% vs 4%， < 0.001）、≥1 个脑叶微出血（94% vs 26%， < 0.001）、既往颅内出血（17% vs 4%， = 0.04）、≥21 个可见的侧脑室周围血管周围间隙（34% vs 4%， < 0.01）和软脑膜强化（70% vs 27%， < 0.001）。BP-PACNS 患者更常出现头痛（56% vs 31%， < 0.01）、运动障碍（56% vs 36%， = 0.02）和非缺血性实质钆增强（82% vs 16%， < 0.001）。CAA-RI 和 BP-PACNS 患者的急性缺血性病变患病率分别为 18%和 22%（ = 0.57）。对 CAA-RI 具有最高特异性的特征是急性蛛网膜下腔出血（98%）、皮质表浅铁沉积（96%）、既往颅内出血（96%）和≥21 个可见的侧脑室周围血管周围间隙（96%）。可能的 CAA-RI 标准在区分活检阳性的 CAA-RI 和 BP-PACNS 时具有 71%的敏感性（95%CI 44%-90%）和 91%的特异性（95%CI 79%-98%）。在缓解后的前 2 年内，CAA-RI 的复发率低于 BP-PACNS（风险比 0.46，95%CI 0.22-0.96， = 0.04）。
CAA-RI 和 BP-PACNS 患者的临床影像学特征不同。CAA-RI 的特异性标志物包括蛛网膜下腔受累的出血征象、既往颅内出血、≥21 个可见的侧脑室周围血管周围间隙和可能的 CAA-RI 标准。在某些情况下，活检仍然是 CAA-RI 诊断的必要手段。在疾病缓解后的前 2 年内，CAA-RI 的复发率低于 BP-PACNS。
